Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Clinical trial NCT05917431 · RECRUITING

Trial details

NCT number: NCT05917431
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Hepatocellular Carcinoma Oligometastatic Disease

Start date: 2023-06-01
Primary completion: 2025-12-30
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.